AXIM BIOTECHNOLOGIES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0137 USD | +11.84% |
|
-8.67% | -27.89% |
| 04-16 | AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-15 | AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding | CI |
| Sales 2022 | 8.88K 12.13K | Sales 2023 | 39.52K 54.02K | Capitalization | 4.52M 6.17M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -8.2M | Net income 2023 | -8M -10.94M | EV / Sales 2022 | 1,218 x |
| Net Debt 2022 | 5.64M 7.72M | Net Debt 2023 | 5.74M 7.84M | EV / Sales 2023 | 259 x |
| P/E ratio 2022 |
-0.69
x | P/E ratio 2023 |
-0.48
x | Employees | 7 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.61% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +11.84% | ||
| 1 week | -8.67% | ||
| Current month | +19.13% | ||
| 1 month | +15.13% | ||
| 3 months | -30.46% | ||
| 6 months | -24.31% | ||
| Current year | -27.89% |
1 week
0.01
0.02
1 month
0.010.02
Current year
0.010.02
1 year
0.010.04
3 years
0.011.22
5 years
0.011.44
10 years
0.0119.80
| Managers | Title | Age | Since |
|---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 16-06-28 |
Kurt Phinney
COO | Chief Operating Officer | - | 23-05-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 17-05-17 |
| Director/Board Member | 76 | 17-05-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.0137 | +11.84% | 126,525 |
| 24-04-25 | 0.0122 | +18.93% | 2,051,159 |
| 24-04-24 | 0.0103 | -5.50% | 880,241 |
| 24-04-23 | 0.0109 | -14.17% | 1,056,387 |
| 24-04-22 | 0.0127 | -15.33% | 724,896 |
Delayed Quote OTC Markets, April 26, 2024 at 03:11 pm
More quotes
Axim Biotechnologies, Inc. is an international healthcare diagnostic solutions development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. It has developed and commercialized two highly specialized point-of-care (POC) diagnostic tests, Ocular Immunoglobulin E (IgE) test and Lactoferrin test, which are designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient DED and non-specific allergic conjunctivitis. In addition, it is also engaged in the development of a quantitative tear MMP-9 test to measure the intensity of inflammation affecting dry eye patients. It has also developed proprietary assays for the detection of QSOX1-L in patients undergoing cancer treatment. Its products also include SARS-CoV-2 neutralizing antibody tests and a fentanyl neutralizing antibody test.
| 1st Jan change | Capi. | |
|---|---|---|
| -27.89% | 3.81M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- AXIM Stock
